Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.

Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG
Lancet Oncol. 2013 14 (4): 371-82

PMID: 23477833 · PMCID: PMC3766955 · DOI:10.1016/S1470-2045(13)70049-4

MeSH Terms (20)

Adult Aged Aged, 80 and over Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols Bone Neoplasms Disease-Free Survival Drug-Related Side Effects and Adverse Reactions Female Humans Male Middle Aged Neoplasm Grading Protein Kinase Inhibitors Receptor, IGF Type 1 Sarcoma Sarcoma Sirolimus TOR Serine-Threonine Kinases

Connections (1)

This publication is referenced by other Labnodes entities: